Skip to content

Study of the potential radioprotective effects of probiotic bacteria to mitigate gastrointestinal complications after conventional radiotherapy

Study of the potential radioprotective effects of probiotic bacteria to mitigate gastrointestinal complications of colorectal cancer after conventional radiotherapy

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210704051788N1
Enrollment
60
Registered
2021-10-10
Start date
2021-10-12
Completion date
Unknown
Last updated
2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Colorectal Cancer. Condition 2: Colorectal Cancer. Malignant neoplasm of colon Malignant neoplasm of rectum

Interventions

Intervention 1: Intervention group: 1-Patients will take two capsules (daily) containing several probiotic strains from one week before the start of treatment until 10 days after the end of radiothera

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Adults with colorectal cancer who are candidates for radiotherapy as part of their treatment

Exclusion criteria

Exclusion criteria: Consumption of narcotic painkillers Existence of acute and chronic gastrointestinal complications before starting treatment Take any antibiotics one week before the start to end of radiotherapy Received radiation therapy in the abdomen and pelvis in recent years Use probiotic supplements during the 15 days before the study and also take other probiotic forms including probiotic yogurt and other fermented foods

Design outcomes

Primary

MeasureTime frame
Quality of life. Timepoint: At the beginning of the study and 8 weeks after the intervention. Method of measurement: Questionnaire.;Gastrointestinal disorders. Timepoint: At the beginning of the study and 6 months after the intervention. Method of measurement: Clinical examination by an oncologist.

Secondary

MeasureTime frame
Thrombocytopenia-Leukopenia-Anemia. Timepoint: At the beginning of the study and 8 weeks after the intervention. Method of measurement: CBC Test(Complete blood count).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamidreza Jamali

Shiraz University of Medical Sciences

jamalihamidreza91@yahoo.com+98 71 3234 9332

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026